On Feb 16, we issued an updated research report on Illumina, Inc. ILMN. The company’s market opportunities continue to expand owing to accelerated demand from clinical and translational customers.

The Genomics Core offers a variety of microarray analysis options for DNA and epigenetic studies. The Illumina BeadArray technology combined with the Illumina iScan Array Scanner allows for analysis ...

Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on year at $1.08 billion. Its non-GAAP profit of $1.34 per share was 14.7% above ...

Illumina's (ILMN-5.63%) first-quarter results were full of exclamation points -- at least from an investor's perspective. Revenue jumped nearly 31% year over year. Adjusted earnings per share more ...

CAMBRIDGE, England--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration with 54gene, a health technology company whose mission is to advance precision medicine capabilities ...

Illumina 's (NASDAQ: ILMN) first-quarter results were full of exclamation points -- at least from an investor's perspective. Revenue jumped nearly 31% year over year. Adjusted earnings per share more ...